biosyn Corporation is a pharmaceutical and biotech company established in 1995 in California. The company is focused on the development, manufacturing and marketing of novel hemocyanin and selenium products.

biosyn hemocyanin and immunocyanin products have since been marketed under the trade name IMMUCOTHEL® and VACMUNE® and are now well recognized quality investigational products and are used extensively as carrier protein for investigation vaccine production and as a tracer molecule in vaccine preparation, as a neoantigen and for immune status evaluation.

biosyn is world leader in the manufacture of high quality, clinical/GMP and research grade hemocyanin product. At present, 3 of the 10 biggest international pharmaceutical companies are using biosyn hemocyanin products for research and development of novel vaccines in advanced stages.

Having successfully registered the biosyn drug product selenase® in Europe, including Russia, as well as in Asian and South American countries, and with the increased interest in selenium usage for clinical investigation in the USA, biosyn filed the Drug Master File with the US FDA in 2008 to enable and support the usage of the biosyn standardized selenium product in investigational studies.

biosyn’s future goal is to ensure quality product availability and regulatory support to its current and new customers for investigational and commercial purposes.